ZNTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zentalis Pharmaceuticals Inc (ZNTL) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The company has weak financial performance, no significant trading trends, and lacks clear positive technical or proprietary trading signals. While there are some positive catalysts in its drug development pipeline, the financial and technical indicators suggest caution.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 41.62, providing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below key support levels (S1: 3.963). The pre-market price is $3.89, which is below the pivot level of $5.178, suggesting limited upside in the short term.
Additionally, preclinical data shows promising results for azenosertib in combination therapies.
Net income and EPS have also declined significantly. Technical indicators are mixed to bearish, and there are no significant insider or hedge fund trading trends.
In Q4 2025, Zentalis reported a 100% YoY revenue decline to $0, a 25.82% YoY drop in net income to -$35.2M, and a 26.87% YoY decline in EPS to -$0.49. Gross margin also fell to 0%. These figures indicate severe financial struggles.
Guggenheim recently raised the price target for Zentalis from $6 to $10, maintaining a Buy rating. This is based on increased probability of success assumptions for its ovarian cancer treatment. However, this optimism is not yet reflected in the stock's technical or financial performance.
